See more : CHIeru Co.,Ltd. (3933.T) Income Statement Analysis – Financial Results
Complete financial analysis of NeuroBo Pharmaceuticals, Inc. (NRBO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeuroBo Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Refex Renewables & Infrastruct (REFEXRENEW.BO) Income Statement Analysis – Financial Results
- Chr. Hansen Holding A/S (CRTSF) Income Statement Analysis – Financial Results
- JTEKT Corporation (JTEKY) Income Statement Analysis – Financial Results
- F & M Bank Corp. (FMBM) Income Statement Analysis – Financial Results
- Performance Shipping Inc. (PSHG) Income Statement Analysis – Financial Results
NeuroBo Pharmaceuticals, Inc. (NRBO)
About NeuroBo Pharmaceuticals, Inc.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 28.00K | 72.00K | 67.00K | 17.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -28.00K | -72.00K | -67.00K | -17.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.16M | 2.78M | 6.55M | 21.87M | 17.48M | 14.31M | 22.69M | 8.74M | 3.99M | 52.00K |
| General & Administrative | 6.73M | 8.64M | 8.75M | 7.85M | 2.70M | 8.49M | 60.00K | 5.96M | 3.18M | 214.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.38M | 0.00 | 0.00 | 0.00 |
| SG&A | 6.73M | 8.64M | 8.75M | 7.85M | 2.70M | 8.49M | 10.44M | 5.96M | 3.18M | 214.00K |
| Other Expenses | 0.00 | -83.00K | 0.00 | -1.00K | 12.15M | -178.00K | 10.44M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.89M | 11.42M | 15.30M | 29.72M | 20.18M | 22.81M | 33.12M | 14.70M | 7.17M | 266.00K |
| Cost & Expenses | 15.89M | 11.42M | 15.30M | 29.72M | 20.18M | 22.81M | 33.12M | 14.70M | 7.17M | 266.00K |
| Interest Income | 461.00K | 2.19K | 14.00K | 39.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 2.19M | 0.00 | 39.00K | 22.00K | 654.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.00K | 28.00K | 72.00K | 67.00K | 17.00K | 6.67M | 60.00K | -17.00K | 2.01M | -1.00K |
| EBITDA | -15.88M | -11.40M | -15.21M | -29.61M | -21.17M | -15.49M | -33.09M | -14.50M | -6.07M | -283.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -15.89M | -19.63M | -15.30M | -29.72M | -20.18M | -22.81M | -33.12M | -14.70M | -8.08M | -266.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.42M | 5.66M | 14.00K | 38.00K | -1.14M | -43.00K | -291.00K | 110.00K | -953.00K | -54.00K |
| Income Before Tax | -12.47M | -13.97M | -15.28M | -29.68M | -21.31M | -23.64M | -33.42M | -14.59M | -9.03M | -320.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.85M | -62.00K | -85.00K | 1.12M | 654.00K | 286.00K | -136.82K | -146.00K | 55.00K |
| Net Income | -12.47M | -6.12M | -15.22M | -29.59M | -22.43M | -23.64M | -33.42M | -14.59M | -9.03M | -320.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.46 | -19.01 | -157.85 | -437.95 | -1.03K | -166.80 | -2.42K | -1.88K | -1.28K | -45.27 |
| EPS Diluted | -2.46 | -19.01 | -157.85 | -437.95 | -1.03K | -166.80 | -2.42K | -1.88K | -1.28K | -45.27 |
| Weighted Avg Shares Out | 5.07M | 321.70K | 96.43K | 67.57K | 21.77K | 141.71K | 13.80K | 7.75K | 7.07K | 7.07K |
| Weighted Avg Shares Out (Dil) | 5.07M | 321.70K | 96.43K | 67.57K | 21.77K | 141.71K | 13.80K | 7.75K | 7.07K | 7.07K |
New Balance send message to Liverpool after Premier League title win
Domestic Equities Market Moderates by 0.38% amid Sustained Bearish Activity
Legrand: Total Number of Shares and Voting Rights
Nigerian Breweries brings the Bears to party, Investors down N20.5 billion |
5 Consumer stocks you should consider for your portfolio | Nairametrics
Domestic Equities Market Dips by 1.17% amid Renewed Profit Taking Activity
Ulrika Jonsson opens up about having had Covid-19 as she talks 'sadness spell'
Liverpool and Nike agree new date as New Balance situation resolved
Gold prices surge, as protests erupt In America | Nairametrics
Source: https://incomestatements.info
Category: Stock Reports